Ambit Health Ventures

Encapsulate specializes in automated tumor-on-a-chip technology, which allows for the growth and preservation of cancer cells outside the body. This innovative approach enables the creation of micro tumors from patients' cancer cells, facilitating the assessment of how these cells respond to various chemotherapy and biotherapy drugs. By evaluating the efficacy of treatments on an individualized basis, Encapsulate's technology aids oncologists in determining effective personalized treatment regimens for cancer patients, starting from the initial diagnosis. This method enhances the ability to tailor cancer therapies to the specific needs of each patient, thereby improving treatment outcomes.

Wavely Diagnostics is pioneering the future of remote digital diagnostics and enabling telehealth growth by leveraging smartphone technology to address pediatric care.

Smartlens is a clinical-stage Med Tech company focused on developing innovative technologies for diagnosing and treating glaucoma, a leading cause of irreversible blindness. Its primary product, miLens, is a microfluidic-based smart contact lens designed for continuous monitoring of intraocular pressure (IOP), addressing the urgent need for home-based monitoring solutions. Current clinical trials indicate that miLens offers an accurate alternative to traditional office-based devices, potentially enhancing early diagnosis and personalized treatment for patients. The technology is non-invasive and utilizes a unique electronics-free sensor, which is supported by a robust portfolio of patents across multiple countries. In addition to its core focus on glaucoma, Smartlens is exploring applications for its technology in monitoring intracranial pressure, associated with neurological disorders and cancers, in collaboration with Stanford University Labs. The company has been recognized for its innovative contributions to medical technology and has gained visibility through various media outlets and industry conferences. Smartlens aims to improve patient outcomes, reduce treatment costs, and mitigate the societal impact of blindness through its cutting-edge solutions.

SOAP Health is a healthcare technology company based in Boca Raton, Florida, founded in 2019. It develops an artificial intelligence-powered platform designed to enhance physician productivity and improve patient outcomes. The platform captures and analyzes detailed patient data before medical visits and integrates with electronic health records to streamline clinical practice. By utilizing a conversational interface, it simplifies patient-reported data collection and risk assessment, producing nearly complete SOAP notes to assist physicians in clinical decision-making. This approach not only helps identify at-risk patients and facilitates early disease detection but also aims to increase patient engagement and satisfaction while reducing errors and liability exposure for healthcare providers.

Wavely Diagnostics is pioneering the future of remote digital diagnostics and enabling telehealth growth by leveraging smartphone technology to address pediatric care.

Smartlens is a clinical-stage Med Tech company focused on developing innovative technologies for diagnosing and treating glaucoma, a leading cause of irreversible blindness. Its primary product, miLens, is a microfluidic-based smart contact lens designed for continuous monitoring of intraocular pressure (IOP), addressing the urgent need for home-based monitoring solutions. Current clinical trials indicate that miLens offers an accurate alternative to traditional office-based devices, potentially enhancing early diagnosis and personalized treatment for patients. The technology is non-invasive and utilizes a unique electronics-free sensor, which is supported by a robust portfolio of patents across multiple countries. In addition to its core focus on glaucoma, Smartlens is exploring applications for its technology in monitoring intracranial pressure, associated with neurological disorders and cancers, in collaboration with Stanford University Labs. The company has been recognized for its innovative contributions to medical technology and has gained visibility through various media outlets and industry conferences. Smartlens aims to improve patient outcomes, reduce treatment costs, and mitigate the societal impact of blindness through its cutting-edge solutions.

Bone Health Technologies, Inc. is a health technology company based in Redwood City, California, focused on developing innovative solutions for individuals with low bone density. Incorporated in 2018, the company has created OsteoBoost, a wearable medical device that provides a non-invasive treatment to prevent osteoporosis. This FDA-cleared device is designed to be worn on the lower back and utilizes whole-body vibration technology to deliver mechanical stimulation to the hips and spine, mimicking the effects of weight-bearing exercise. Clinical studies have demonstrated OsteoBoost's efficacy in significantly slowing down the loss of bone density and strength, particularly in postmenopausal women with osteopenia. By offering a convenient, pain-free alternative to pharmacological treatments, Bone Health Technologies aims to improve health outcomes for the approximately 64 million Americans at risk of osteoporotic fractures.